| 7.9 -0.86 (-9.82%) | 03-03 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.8 |
1-year : | 10.48 |
| Resists | First : | 8.39 |
Second : | 8.97 |
| Pivot price | 8.22  |
|||
| Supports | First : | 7.44 |
Second : | 6.19 |
| MAs | MA(5) : | 8.41 |
MA(20) : | 8.11 |
| MA(100) : | 7.82 |
MA(250) : | 8.16 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 51.3 |
D(3) : | 61.8 |
| RSI | RSI(14): 46.6 |
|||
| 52-week | High : | 13.75 | Low : | 6.11 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ GYRE ] has closed above bottom band by 20.5%. Bollinger Bands are 10.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.78 - 8.82 | 8.82 - 8.87 |
| Low: | 7.71 - 7.76 | 7.76 - 7.81 |
| Close: | 7.81 - 7.89 | 7.89 - 7.96 |
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Tue, 03 Mar 2026
GYRE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Tue, 03 Mar 2026
Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction - Yahoo Finance
Mon, 02 Mar 2026
Gyre, Cullgen Merge In $300M All-Stock Deal - Law360
Mon, 02 Mar 2026
Gyre Therapeutics (NASDAQ:GYRE) Trading Up 8.2% - Should You Buy? - MarketBeat
Mon, 02 Mar 2026
Pulmatrix Shares Dive As Privately-Held Pharma Company Chooses To Merge With Gyre Therapeutics Instead - Stocktwits
Mon, 02 Mar 2026
Gyre Therapeutics to Acquire Cullgen in All-Stock Merger - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 96 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 87 (%) |
| Held by Institutions | 3.7 (%) |
| Shares Short | 1,420 (K) |
| Shares Short P.Month | 1,380 (K) |
| EPS | 0.03 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.12 |
| Profit Margin | 6.1 % |
| Operating Margin | 22.6 % |
| Return on Assets (ttm) | 5.2 % |
| Return on Equity (ttm) | 10 % |
| Qtrly Rev. Growth | 19.8 % |
| Gross Profit (p.s.) | 1.06 |
| Sales Per Share | 1.11 |
| EBITDA (p.s.) | 0.14 |
| Qtrly Earnings Growth | 166.1 % |
| Operating Cash Flow | 4 (M) |
| Levered Free Cash Flow | 3 (M) |
| PE Ratio | 197.5 |
| PEG Ratio | 0 |
| Price to Book value | 7.05 |
| Price to Sales | 7.09 |
| Price to Cash Flow | 196.13 |
| Dividend | 3.59 |
| Forward Dividend | 0 |
| Dividend Yield | 45.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|